Overview

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Acne vulgaris is a common disease of both males and females, usually manifesting initially during adolescence. The use of retinoic acid analogues such as adapalene, tazarotene and isotretinoin are also commonly prescribed to treat inflammation; dysregulated sebum production and comedonal acne. This study seeks to evaluate the efficacy and safety of concomitant use of both AMZEEQ® and oral isotretinoin compared to oral isotretinoin only use and to explore sequence dosing of both products as part of a long-term management protocol for acne vulgaris.
Phase:
Phase 4
Details
Lead Sponsor:
Edward Lain, MD
Collaborator:
Vyne Therapeutics Inc.
Treatments:
Isotretinoin
Minocycline